Systemic lupus erythematosus is a chronic, multisystem, inflammatory,
autoimmune disorder characterized by formation of autoantibodies
directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease
activity varies over time in a single patient. Majority of patients have
arthralgia of the hand.
A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.